What are the most effective treatments for MRSA infections. How do vancomycin, teicoplanin, and newer antibiotics compare in efficacy. What are the latest guidelines for managing MRSA bacteremia. How can clinicians optimize antibiotic therapy for MRSA.

Understanding MRSA and Its Treatment Challenges

Methicillin-resistant Staphylococcus aureus (MRSA) is a significant healthcare concern due to its resistance to many common antibiotics. MRSA infections, particularly bacteremia, pose substantial treatment challenges and are associated with high morbidity and mortality rates. Effective management of MRSA infections requires a thorough understanding of available treatment options and their optimal use.

What is MRSA?

MRSA is a strain of Staphylococcus aureus bacteria that has developed resistance to methicillin and other beta-lactam antibiotics. This resistance makes MRSA infections particularly difficult to treat, as many standard antibiotic regimens are ineffective against this pathogen.

Why is MRSA treatment challenging?

The treatment of MRSA infections is challenging due to several factors:

• Limited antibiotic options due to widespread resistance
• Potential for development of further resistance during treatment
• Variability in antibiotic efficacy depending on infection site and severity
• Need for careful dosing and monitoring to optimize treatment outcomes

Vancomycin: The Traditional Gold Standard for MRSA Treatment

Vancomycin has long been considered the gold standard for treating MRSA infections. However, recent research has raised concerns about its efficacy in certain situations.

How effective is vancomycin against MRSA?

Vancomycin remains an effective treatment option for many MRSA infections. However, its efficacy may be compromised in cases where the minimum inhibitory concentration (MIC) is elevated. A systematic review and meta-analysis by Kalil et al. found an association between higher vancomycin MICs and increased mortality in patients with Staphylococcus aureus bloodstream infections.

How should vancomycin be dosed for optimal efficacy?

Proper dosing of vancomycin is crucial for achieving optimal treatment outcomes. Neely et al. investigated whether current vancomycin trough concentration targets are adequate for optimal dosing. Their findings suggest that maintaining higher trough concentrations may be necessary to achieve therapeutic goals, particularly in cases of severe MRSA infections.

Teicoplanin: An Alternative Glycopeptide Antibiotic

Teicoplanin is another glycopeptide antibiotic that has shown promise in treating MRSA infections. Its efficacy has been compared to vancomycin in several studies.

How does teicoplanin compare to vancomycin?

A Cochrane review by Cavalcanti et al. evaluated the efficacy of teicoplanin versus vancomycin for proven or suspected infections. While the review found no significant difference in overall treatment failure between the two antibiotics, teicoplanin was associated with a lower risk of nephrotoxicity.

A multicenter prospective observational study by Yoon et al. compared the efficacy and safety of vancomycin versus teicoplanin in patients with healthcare-associated MRSA bacteremia. The study found comparable clinical outcomes between the two treatments, with teicoplanin showing a more favorable safety profile.

Emerging Therapies: Telavancin and Daptomycin

As MRSA continues to evolve and develop resistance, newer antibiotics have been developed to address these challenges. Telavancin and daptomycin are two such agents that have shown promise in treating MRSA infections.

What is telavancin and how effective is it against MRSA?

Telavancin is a semisynthetic lipoglycopeptide antibiotic with multiple mechanisms of action against gram-positive bacteria, including MRSA. Karlowsky et al. reviewed the mechanisms of action, in vitro activity, and potential resistance mechanisms of telavancin. The ASSURE study, a randomized Phase 2 trial conducted by Stryjewski et al., compared telavancin to standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia, demonstrating comparable efficacy.

How does daptomycin perform in treating MRSA bacteremia?

Daptomycin is a cyclic lipopeptide antibiotic that has shown efficacy against MRSA infections, including bacteremia. The landmark study by Fowler et al. compared daptomycin to standard therapy for Staphylococcus aureus bacteremia and endocarditis. The study found that daptomycin was non-inferior to standard therapy, with a better safety profile in some aspects.

Subsequent studies have further explored the efficacy of daptomycin, particularly in cases where vancomycin may be less effective. Moore et al. and Murray et al. conducted case-control and matched cohort studies, respectively, comparing daptomycin to vancomycin for MRSA bloodstream infections with high vancomycin MICs. Both studies suggested potential benefits of early daptomycin use in these scenarios.

Ceftaroline: A Novel Cephalosporin for MRSA Treatment

Ceftaroline represents a breakthrough in cephalosporin antibiotics, as it demonstrates activity against MRSA, unlike most other cephalosporins.

How does ceftaroline work against MRSA?

Saravolatz et al. reviewed the mechanism of action and clinical efficacy of ceftaroline against MRSA. The antibiotic’s unique ability to bind to penicillin-binding protein 2a (PBP2a) allows it to overcome the primary mechanism of methicillin resistance in MRSA.

Otero et al. provided further insights into the molecular basis of ceftaroline’s efficacy, demonstrating how it enables allosteric control of PBP2a in Staphylococcus aureus, thus overcoming methicillin resistance while maintaining physiological function.

When might ceftaroline be used for MRSA infections?

Ceftaroline has shown promise as a salvage therapy option for MRSA infections. Espedido et al. discussed the potential use of ceftaroline fosamil as a salvage therapy for persistent MRSA bacteremia. This approach may be particularly valuable in cases where standard therapies have failed or are contraindicated.

Optimizing Antibiotic Therapy for MRSA Infections

Effective management of MRSA infections requires careful consideration of various factors to optimize antibiotic therapy.

How can clinicians choose the most appropriate antibiotic for MRSA infections?

Selecting the most appropriate antibiotic for MRSA infections involves considering several factors:

1. Local resistance patterns and antibiotic susceptibility data
2. Site and severity of infection
3. Patient-specific factors (e.g., renal function, drug allergies)
4. Potential for drug interactions
5. Cost and availability of different antibiotics

What strategies can improve treatment outcomes for MRSA bacteremia?

To improve outcomes in MRSA bacteremia, clinicians should consider the following strategies:

• Early initiation of appropriate antibiotic therapy
• Proper dosing and monitoring of antibiotic levels (e.g., vancomycin trough concentrations)
• Source control measures (e.g., removal of infected catheters or drainage of abscesses)
• Consideration of combination therapy in severe or refractory cases
• Regular reassessment of treatment response and adjustment of therapy as needed

Future Directions in MRSA Treatment

As MRSA continues to evolve and develop resistance to existing antibiotics, ongoing research is crucial to develop new treatment strategies and optimize current therapies.

What new antibiotics are in development for MRSA infections?

Several new antibiotics are currently in various stages of development for MRSA infections. These include novel classes of antibiotics as well as modifications of existing classes to overcome resistance mechanisms. Ongoing clinical trials are evaluating the safety and efficacy of these new agents.

How might combination therapy improve MRSA treatment outcomes?

Combination therapy, using multiple antibiotics with different mechanisms of action, is an area of active research for MRSA infections. This approach may help overcome resistance, enhance bactericidal activity, and potentially reduce the emergence of further resistance during treatment. Studies are ongoing to determine the most effective antibiotic combinations for various MRSA infection scenarios.

Implementing Evidence-Based Guidelines for MRSA Management

Adhering to evidence-based guidelines is crucial for optimizing MRSA treatment outcomes and preventing the development of further antibiotic resistance.

What are the current guidelines for managing MRSA infections?

The Infectious Diseases Society of America (IDSA) has published comprehensive guidelines for the treatment of MRSA infections in adults and children. These guidelines, authored by Liu et al., provide recommendations for various MRSA infection scenarios, including skin and soft tissue infections, pneumonia, and bacteremia.

How often should guidelines be updated to reflect new evidence?

Given the rapidly evolving landscape of MRSA treatment and the emergence of new antibiotics, regular updates to clinical guidelines are essential. Most organizations aim to review and update their guidelines every 3-5 years, or sooner if significant new evidence emerges that could substantially change treatment recommendations.

In conclusion, the management of MRSA infections remains a significant challenge in healthcare settings. While traditional antibiotics like vancomycin continue to play a crucial role, newer agents such as daptomycin, telavancin, and ceftaroline offer additional options for clinicians. Optimizing antibiotic therapy through careful drug selection, proper dosing, and consideration of combination approaches is essential for improving outcomes in MRSA infections. Ongoing research and adherence to evidence-based guidelines will be crucial in addressing the evolving challenges posed by this resistant pathogen.

Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE. J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55. [PubMed] [Google Scholar]

2. Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA. 2014;312:1552–1564. [PubMed] [Google Scholar]

3. Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58:309–316. [PMC free article] [PubMed] [Google Scholar]

4. Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A, Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013;41:255–260. [PubMed] [Google Scholar]

5. Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010:CD007022. [PubMed] [Google Scholar]

6. Yoon YK, Park DW, Sohn JW, Kim HY, Kim YS, Lee CS, Lee MS, Ryu SY, Jang HC, Choi YJ, Kang CI, Choi HJ, Lee SS, Kim SW, Kim SI, Kim ES, Kim JY, Yang KS, Peck KR, Kim MJ. Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2014;58:317–324. [PMC free article] [PubMed] [Google Scholar]

7. Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clin Infect Dis. 2015;61(Suppl 2):S58–68. [PubMed] [Google Scholar]

8. Stryjewski ME, Lentnek A, O’Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG, Jr, Barriere SL, Kitt MM, Corey GR. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014;14:289. [PMC free article] [PubMed] [Google Scholar]

9. National Institutes of Health. A phase 3 telavancin Staphylococcus aureus (S. Aureus) bacteremia trial. [Accessed June 30 2015]. Available at: https://clinicaltrials.gov/ct2/show/{“type”:”clinical-trial”,”attrs”:{“text”:”NCT02208063″,”term_id”:”NCT02208063″}}NCT02208063.

10. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
. N Engl J Med. 2006;355:653–665. [PubMed] [Google Scholar]

11. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994–1000. [PubMed] [Google Scholar]

12. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54:51–58. [PubMed] [Google Scholar]

13. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis. 2013;56:1562–1569. [PubMed] [Google Scholar]

14. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus
. Clin Infect Dis. 2011;52:1156–1163. [PubMed] [Google Scholar]

15. Otero LH, Rojas-Altuve A, Llarrull LI, Carrasco-López C, Kumarasiri M, Lastochkin E, Fishovitz J, Dawley M, Hesek D, Lee M, Johnson JW, Fisher JF, Chang M, Mobashery S, Hermoso JA. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci USA. 2013;110:16808–16813. [PMC free article] [PubMed] [Google Scholar]

16. Espedido BA, Jensen SO, van Hal SJ. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia. J Antimicrob Chemother. 2015;70:797–801. [PubMed] [Google Scholar]

17. Vazquez JA, Maggiore CR, Cole P, Smith A, Jandourek A, Friedland HD. Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Infect Dis Clin Pract. 2015;23:39–43. [Baltim Md] [PMC free article] [PubMed] [Google Scholar]

18. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541–2546. [PMC free article] [PubMed] [Google Scholar]

19. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135–142. [PubMed] [Google Scholar]

20. Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis. 2006;42:729–730. [PubMed] [Google Scholar]

21. Jang HC, Kim SH, Kim KH, Kim CJ, Lee S, Song KH, Jeon JH, Park WB, Kim HB, Park SW, Kim NJ, Kim EC, Oh MD, Choe KW. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis. 2009;49:395–401. [PubMed] [Google Scholar]

22. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, Croos-Dabrera RV, Kunkel MJ, Knirsch C. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48:203–212. [PubMed] [Google Scholar]

23. Park HJ, Kim SH, Kim MJ, Lee YM, Park SY, Moon SM, Park KH, Chong YP, Lee SO, Choi SH, Woo JH, Kim YS. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Infect. 2012;65:505–512. [PubMed] [Google Scholar]

24. Sánchez García M, De la Torre MA, Morales G, Peláez B, Tolón MJ, Domingo S, Candel FJ, Andrade R, Arribi A, García N, Martínez Sagasti F, Fereres J, Picazo J. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303:2260–2264. [PubMed] [Google Scholar]

25. Rybak JM, Marx K, Martin CA. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy. 2014;34:1198–1208. [PubMed] [Google Scholar]

26. Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2015;59:3252–3256. [PMC free article] [PubMed] [Google Scholar]

27. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75:331–336. [PubMed] [Google Scholar]

28. Gardiner D, Dukart G, Cooper A, Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis. 2010;50:229–238. [PubMed] [Google Scholar]

29. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57:1756–1762. [PMC free article] [PubMed] [Google Scholar]

30. Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, Mercier RC. beta-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother. 2014;58:102–109. [PMC free article] [PubMed] [Google Scholar]

31. Davis JS, Sud A, O’Sullivan MV, Robinson JO, Ferguson PE, Foo H, van Hal SJ, Ralph AP, Howden BP, Binks PM, Kirby A, Tong SY.
Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA) study group; Australasian Society for Infectious Diseases Clinical Research Network. Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62:173–180. [PubMed] [Google Scholar]

32. Chambers HF, Basuino L, Hamilton SM, Choo EJ, Moise P. Daptomycin- β-lactam combinations in a rabbit model of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2016;60:3976–3979. [PMC free article] [PubMed] [Google Scholar]

33. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36:1317–1333. [PubMed] [Google Scholar]

Methicillin-Resistant Staphylococcus Aureus (MRSA)

• “Methicillin-Resistant Staphylococcus aureus” is also available in Portable Document Format (PDF, 47KB, 2pg. )
• Versión en español
• Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)
• Antibiotic Resistance

What is MRSA?

MRSA refers to a type of bacteria (Staphylococcus aureus) that is resistant to many antibiotics. It is a common cause of hospital-acquired infections.

Who gets MRSA?

Anyone can get MRSA, but it is found most often in hospitalized patients.

What are the symptoms associated with MRSA infection?

MRSA infections can cause a broad range of symptoms depending on the part of the body that is infected. These may include surgical wounds, burns, catheter sites, eye, skin and blood. Infection often results in redness, swelling and tenderness at the site of infection. Sometimes, people may carry MRSA without having any symptoms.

How is it transmitted?

The staph bacteria is generally spread through direct contact with the hands of a health care worker or patient who is infected or carrying the organism.

How long can an infected person carry MRSA?

Some people can carry MRSA for days to many months, even after their infection has been treated.

How are MRSA infections diagnosed?

MRSA infections can be diagnosed when a doctor obtains a sample or specimen from the site of infection and submits it to a laboratory. The laboratory places the specimen on a special “culture” plate containing nutrients, incubates the plate in a warmer and then identifies the bacteria. The final step is for the laboratory to conduct tests using various antibiotics to determine if the bacteria are resistant (able to withstand or tolerate) or sensitive (susceptible to killing) to select antibiotics.

What is the treatment for MRSA?

Although MRSA cannot be effectively treated with antibiotics such as methicillin, nafcillin, cephalosporin or penicillin, it can usually be treated with an antibiotic called vancomycin. Recently, however, a few strains of Staphylococcus aureus have even developed some degree of resistance to vancomycin.